Dietary Effects of Mead Acid on -methyl--nitrosourea-induced Mammary Cancers in Female Sprague-Dawley Rats

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2016 Feb 13

PMID 26870330

Citations 7

Authors

Yuichi Kinoshita

Katsuhiko Yoshizawa

Kei Hamazaki

Yuko Emoto

Takashi Yuri

Michiko Yuki

Hiroshi Kawashima

Nobuaki Shikata

Airo Tsubura

Affiliations

Soon will be listed here.

Abstract

The effect of mead acid (MA; 5,8,11-eicosatrienoic acid) on the suppression of the development and growth of -methyl--nitrosourea (MNU)-induced mammary cancer in female Sprague-Dawley rats was examined. The MA diet (2.4% MA) or control (CTR) diet (0% MA) was started at 6 weeks of age, MNU was injected intraperitoneally at 7 weeks of age, and the rats were maintained on the respective diets for the whole experimental period (until 19 weeks of age). All induced mammary tumors were luminal A subtype carcinomas (estrogen and progesterone receptor positive and HER2/neu negative). The MA diet significantly suppressed the initiation and promotion phases of mammary carcinogenesis; MA suppressed the development (incidence, 61.5 vs. 100%; multiplicity, 2.1 vs. 4.5) and the growth (final tumor weight, 427.1 vs. 1,796.3 mg) of mammary cancers by suppressing cell proliferation, but not by accelerating cell death. There were evident changes in the major fatty acid composition of n-3, n-6, and n-9 fatty acids in the serum of the MA diet group; there was a significant increase in MA and significant decreases in oleic acid (OA), linoleic acid, arachidonic acid and docosahexaenoic acid. In non-tumorous mammary tissue, there was a significant increase in MA and a significant decrease in OA in the MA diet group. The n-6/n-3 ratios in serum and mammary tissue of the MA diet group were significantly decreased. The MA diet suppressed MNU-induced luminal A mammary cancer by lowering cancer cell proliferation. Therefore, MA may be a chemopreventive and chemotherapeutic agent. In addition to hormone therapy, MA supplementation may be a beneficial chemotherapeutic agent for the luminal A subtype of breast cancer.

Citing Articles

DPP3 promotes breast cancer tumorigenesis by stabilizing FASN and promoting lipid synthesis.

Fu X, Li X, Wang W, Li J Acta Biochim Biophys Sin (Shanghai). 2024; 56(5):805-818.

PMID: 38655619 PMC: 11177116. DOI: 10.3724/abbs.2024054.

Non-targeted LC-MS/MS metabolomic profiling of human plasma uncovers a novel Mediterranean diet biomarker panel.

Macias S, Yilmaz A, Kirma J, Moore S, Woodside J, Graham S Metabolomics. 2023; 20(1):3.

PMID: 38066384 PMC: 10709258. DOI: 10.1007/s11306-023-02058-y.

The physiological and pathological properties of Mead acid, an endogenous multifunctional n-9 polyunsaturated fatty acid.

Kawashima H, Yoshizawa K Lipids Health Dis. 2023; 22(1):172.

PMID: 37838679 PMC: 10576882. DOI: 10.1186/s12944-023-01937-6.

Omega-9 fatty acids: potential roles in inflammation and cancer management.

Farag M, Gad M J Genet Eng Biotechnol. 2022; 20(1):48.

PMID: 35294666 PMC: 8927560. DOI: 10.1186/s43141-022-00329-0.

Development of mammary cancer in γ-irradiated F1 hybrids of susceptible Sprague-Dawley and resistant Copenhagen rats, with copy-number losses that pinpoint potential tumor suppressors.

Nishimura M, Daino K, Fukuda M, Tanaka I, Moriyama H, Showler K PLoS One. 2021; 16(8):e0255968.

PMID: 34388197 PMC: 8362979. DOI: 10.1371/journal.pone.0255968.

References

Trichopoulou A, Lagiou P, Kuper H, Trichopoulos D . Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prev. 2000; 9(9):869-73. View

Pouchieu C, Chajes V, Laporte F, Kesse-Guyot E, Galan P, Hercberg S . Prospective associations between plasma saturated, monounsaturated and polyunsaturated fatty acids and overall and breast cancer risk - modulation by antioxidants: a nested case-control study. PLoS One. 2014; 9(2):e90442. PMC: 3937383. DOI: 10.1371/journal.pone.0090442. View

Kinoshita Y, Yoshizawa K, Hamazaki K, Emoto Y, Yuri T, Yuki M . Mead acid inhibits the growth of KPL-1 human breast cancer cells in vitro and in vivo. Oncol Rep. 2014; 32(4):1385-94. DOI: 10.3892/or.2014.3390. View

Lips E, Mulder L, de Ronde J, Mandjes I, Koolen B, Wessels L . Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013; 140(1):63-71. PMC: 3706735. DOI: 10.1007/s10549-013-2620-0. View

Ichi I, Kono N, Arita Y, Haga S, Arisawa K, Yamano M . Identification of genes and pathways involved in the synthesis of Mead acid (20:3n-9), an indicator of essential fatty acid deficiency. Biochim Biophys Acta. 2013; 1841(1):204-13. DOI: 10.1016/j.bbalip.2013.10.013. View

Zhu Z, Jiang W, McGinley J, Prokopczyk B, Richie Jr J, El Bayoumy K . Mammary gland density predicts the cancer inhibitory activity of the N-3 to N-6 ratio of dietary fat. Cancer Prev Res (Phila). 2011; 4(10):1675-85. DOI: 10.1158/1940-6207.CAPR-11-0175. View

Hamazaki T, Nagasawa T, Hamazaki K, Itomura M . Inhibitory effect of 5,8,11-eicosatrienoic acid on angiogenesis. Prostaglandins Leukot Essent Fatty Acids. 2012; 86(6):221-4. DOI: 10.1016/j.plefa.2012.04.004. View

Heyd V, Eynard A . Effects of eicosatrienoic acid (20:3 n-9, Mead's acid) on some promalignant-related properties of three human cancer cell lines. Prostaglandins Other Lipid Mediat. 2003; 71(3-4):177-88. DOI: 10.1016/s1098-8823(03)00037-6. View

Okuyama H, Kobayashi T, Watanabe S . Dietary fatty acids--the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Prog Lipid Res. 1996; 35(4):409-57. DOI: 10.1016/s0163-7827(96)00012-4. View

10.

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

11.

Yang B, Ren X, Fu Y, Gao J, Li D . Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies. BMC Cancer. 2014; 14:105. PMC: 4016587. DOI: 10.1186/1471-2407-14-105. View

12.

Chang N, Wu C, Chen D, Yeh C, Lin C . High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J Nutr Biochem. 2012; 24(1):274-81. DOI: 10.1016/j.jnutbio.2012.06.005. View

13.

Yuri T, Danbara N, Tsujita-Kyutoku M, Fukunaga K, Takada H, Inoue Y . Dietary docosahexaenoic acid suppresses N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid. Nutr Cancer. 2003; 45(2):211-7. DOI: 10.1207/S15327914NC4502_11. View

14.

Freedman L, Kipnis V, Schatzkin A, Potischman N . Methods of epidemiology: evaluating the fat-breast cancer hypothesis--comparing dietary instruments and other developments. Cancer J. 2008; 14(2):69-74. PMC: 2496993. DOI: 10.1097/PPO.0b013e31816a5e02. View

15.

Takata T, Minoura T, Takada H, Sakaguchi M, Yamamura M, Hioki K . Specific inhibitory effect of dietary eicosapentaenoic acid on N-nitroso-N-methylurea-induced mammary carcinogenesis in female Sprague-Dawley rats. Carcinogenesis. 1990; 11(11):2015-9. DOI: 10.1093/carcin/11.11.2015. View

16.

Kanematsu S, Yoshizawa K, Uehara N, Miki H, Sasaki T, Kuro M . Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice. Oncol Rep. 2011; 26(3):603-8. DOI: 10.3892/or.2011.1311. View

17.

Senzaki H, Iwamoto S, Ogura E, Kiyozuka Y, Arita S, Kurebayashi J . Dietary effects of fatty acids on growth and metastasis of KPL-1 human breast cancer cells in vivo and in vitro. Anticancer Res. 1998; 18(3A):1621-7. View

18.

COHEN L, Thompson D, Maeura Y, Choi K, Blank M, Rose D . Dietary fat and mammary cancer. I. Promoting effects of different dietary fats on N-nitrosomethylurea-induced rat mammary tumorigenesis. J Natl Cancer Inst. 1986; 77(1):33-42. View

19.

Kurebayashi J, Kanomata N, Moriya T, Kozuka Y, Watanabe M, Sonoo H . Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer. 2010; 10:568. PMC: 2967550. DOI: 10.1186/1471-2407-10-568. View

20.

Russo J . Significance of rat mammary tumors for human risk assessment. Toxicol Pathol. 2015; 43(2):145-70. PMC: 4358771. DOI: 10.1177/0192623314532036. View